Overview

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With

Status:
Unknown status

Trial end date:
2020-03-30

Target enrollment:

Participant gender:

Summary

Phase 3b, single arm, simplification study with dual therapy including Lamivudine (300 mg QD) plus Raltegravir (1200 mg QD) in virologically suppressed HIV-1 infected patients experiencing inconvenience, toxicity, negative impact on comorbidities or risk of drug-drug interactions with their current regimen.

Phase:

Phase 3

Details

Lead Sponsor:

David Garcia Cinca

Collaborators:

Fundació Clínic per a la Recerca Biomèdica
Fundacion Clinic per a la Recerca Biomédica

Treatments:

Lamivudine
Raltegravir Potassium